Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer

Sandra Troup, Catherine Njue, Erich V. Kliewer, Michelle Parisien, Cal Roskelley, Shukti Chakravarti, Peter J. Roughley, Leigh C. Murphy, Peter H. Watson

Research output: Contribution to journalArticle

Abstract

Purpose: To examine the prognostic significance of lumican and decorin, two abundant small leucine-rich proteoglycans in breast tissue stroma. Experimental design: Lumican and decorin expression was examined in a cohort of 140 invasive breast carcinomas by Western blot analysis. All cases were axillary lymph node-negative and treated by adjuvant endocrine therapy. Results: Lumican and decorin expression was highly correlated (r = 0.45, P <0.0001), but although low levels of lumican were associated with large tumor size (P = 0.0496), negative estrogen receptor (P = 0.0024) and progesterone receptor status (P = 0.0116), and increased host inflammatory response (P = 0.0077), low decorin levels were associated only with large tumor size (P = 0.0496). However, using univariate analysis, low levels of lumican and decorin were both associated with a shorter time to progression (P = 0.0013 and 0.0262) and poorer survival (P = 0.001 and 0.0076). In multivariate analysis using the Cox regression model, low decorin was also shown to be an independent predictive factor for recurrence (hazard ratio 2.25: 95% confidence interval 1-5, P = 0.047) and survival (hazard ratio 3.39: 95% confidence interval 1.2-9.6, P = 0.021). Conclusions: These results suggest that low levels of small leucine-rich proteoglycans in breast tumors may be associated with a worse prognosis in lymph node-negative invasive breast carcinomas and warrant further study with larger patient cohorts.

Original languageEnglish (US)
Pages (from-to)207-214
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number1 I
StatePublished - Jan 1 2003

Fingerprint

Decorin
Breast Neoplasms
Lymph Nodes
Confidence Intervals
Survival
Progesterone Receptors
Proportional Hazards Models
Estrogen Receptors
Small Leucine-Rich Proteoglycans
Lumican
Neoplasms
Breast
Research Design
Multivariate Analysis
Western Blotting
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Troup, S., Njue, C., Kliewer, E. V., Parisien, M., Roskelley, C., Chakravarti, S., ... Watson, P. H. (2003). Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clinical Cancer Research, 9(1 I), 207-214.

Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. / Troup, Sandra; Njue, Catherine; Kliewer, Erich V.; Parisien, Michelle; Roskelley, Cal; Chakravarti, Shukti; Roughley, Peter J.; Murphy, Leigh C.; Watson, Peter H.

In: Clinical Cancer Research, Vol. 9, No. 1 I, 01.01.2003, p. 207-214.

Research output: Contribution to journalArticle

Troup, S, Njue, C, Kliewer, EV, Parisien, M, Roskelley, C, Chakravarti, S, Roughley, PJ, Murphy, LC & Watson, PH 2003, 'Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer', Clinical Cancer Research, vol. 9, no. 1 I, pp. 207-214.
Troup, Sandra ; Njue, Catherine ; Kliewer, Erich V. ; Parisien, Michelle ; Roskelley, Cal ; Chakravarti, Shukti ; Roughley, Peter J. ; Murphy, Leigh C. ; Watson, Peter H. / Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. In: Clinical Cancer Research. 2003 ; Vol. 9, No. 1 I. pp. 207-214.
@article{5c9f5b1a69e64bc099ac87223dcc63fb,
title = "Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer",
abstract = "Purpose: To examine the prognostic significance of lumican and decorin, two abundant small leucine-rich proteoglycans in breast tissue stroma. Experimental design: Lumican and decorin expression was examined in a cohort of 140 invasive breast carcinomas by Western blot analysis. All cases were axillary lymph node-negative and treated by adjuvant endocrine therapy. Results: Lumican and decorin expression was highly correlated (r = 0.45, P <0.0001), but although low levels of lumican were associated with large tumor size (P = 0.0496), negative estrogen receptor (P = 0.0024) and progesterone receptor status (P = 0.0116), and increased host inflammatory response (P = 0.0077), low decorin levels were associated only with large tumor size (P = 0.0496). However, using univariate analysis, low levels of lumican and decorin were both associated with a shorter time to progression (P = 0.0013 and 0.0262) and poorer survival (P = 0.001 and 0.0076). In multivariate analysis using the Cox regression model, low decorin was also shown to be an independent predictive factor for recurrence (hazard ratio 2.25: 95{\%} confidence interval 1-5, P = 0.047) and survival (hazard ratio 3.39: 95{\%} confidence interval 1.2-9.6, P = 0.021). Conclusions: These results suggest that low levels of small leucine-rich proteoglycans in breast tumors may be associated with a worse prognosis in lymph node-negative invasive breast carcinomas and warrant further study with larger patient cohorts.",
author = "Sandra Troup and Catherine Njue and Kliewer, {Erich V.} and Michelle Parisien and Cal Roskelley and Shukti Chakravarti and Roughley, {Peter J.} and Murphy, {Leigh C.} and Watson, {Peter H.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "207--214",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1 I",

}

TY - JOUR

T1 - Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer

AU - Troup, Sandra

AU - Njue, Catherine

AU - Kliewer, Erich V.

AU - Parisien, Michelle

AU - Roskelley, Cal

AU - Chakravarti, Shukti

AU - Roughley, Peter J.

AU - Murphy, Leigh C.

AU - Watson, Peter H.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Purpose: To examine the prognostic significance of lumican and decorin, two abundant small leucine-rich proteoglycans in breast tissue stroma. Experimental design: Lumican and decorin expression was examined in a cohort of 140 invasive breast carcinomas by Western blot analysis. All cases were axillary lymph node-negative and treated by adjuvant endocrine therapy. Results: Lumican and decorin expression was highly correlated (r = 0.45, P <0.0001), but although low levels of lumican were associated with large tumor size (P = 0.0496), negative estrogen receptor (P = 0.0024) and progesterone receptor status (P = 0.0116), and increased host inflammatory response (P = 0.0077), low decorin levels were associated only with large tumor size (P = 0.0496). However, using univariate analysis, low levels of lumican and decorin were both associated with a shorter time to progression (P = 0.0013 and 0.0262) and poorer survival (P = 0.001 and 0.0076). In multivariate analysis using the Cox regression model, low decorin was also shown to be an independent predictive factor for recurrence (hazard ratio 2.25: 95% confidence interval 1-5, P = 0.047) and survival (hazard ratio 3.39: 95% confidence interval 1.2-9.6, P = 0.021). Conclusions: These results suggest that low levels of small leucine-rich proteoglycans in breast tumors may be associated with a worse prognosis in lymph node-negative invasive breast carcinomas and warrant further study with larger patient cohorts.

AB - Purpose: To examine the prognostic significance of lumican and decorin, two abundant small leucine-rich proteoglycans in breast tissue stroma. Experimental design: Lumican and decorin expression was examined in a cohort of 140 invasive breast carcinomas by Western blot analysis. All cases were axillary lymph node-negative and treated by adjuvant endocrine therapy. Results: Lumican and decorin expression was highly correlated (r = 0.45, P <0.0001), but although low levels of lumican were associated with large tumor size (P = 0.0496), negative estrogen receptor (P = 0.0024) and progesterone receptor status (P = 0.0116), and increased host inflammatory response (P = 0.0077), low decorin levels were associated only with large tumor size (P = 0.0496). However, using univariate analysis, low levels of lumican and decorin were both associated with a shorter time to progression (P = 0.0013 and 0.0262) and poorer survival (P = 0.001 and 0.0076). In multivariate analysis using the Cox regression model, low decorin was also shown to be an independent predictive factor for recurrence (hazard ratio 2.25: 95% confidence interval 1-5, P = 0.047) and survival (hazard ratio 3.39: 95% confidence interval 1.2-9.6, P = 0.021). Conclusions: These results suggest that low levels of small leucine-rich proteoglycans in breast tumors may be associated with a worse prognosis in lymph node-negative invasive breast carcinomas and warrant further study with larger patient cohorts.

UR - http://www.scopus.com/inward/record.url?scp=12244311868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244311868&partnerID=8YFLogxK

M3 - Article

C2 - 12538471

AN - SCOPUS:12244311868

VL - 9

SP - 207

EP - 214

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1 I

ER -